# Comparison Of Two Tablet Formulations Of SB-568859

> **NCT00470145** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 28 (actual)

## Conditions studied

- Atherosclerosis

## Interventions

- **DRUG:** SB-568859

## Key facts

- **NCT ID:** NCT00470145
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2012-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00470145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00470145, "Comparison Of Two Tablet Formulations Of SB-568859". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00470145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*